Altimmune, Inc. Class Action Lawsuit - ALT

The filed complaint alleges that Altimmune, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Altimmune overstated the potential for its lead product candidate, pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the ALT class action lawsuit, you must have incurred a loss on shares of Altimmune purchased during the class period listed above.

If you suffered a loss in Altimmune during the relevant time frame or pursuant to the relevant offering(s), you have until July 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.